
Hims & Hers faces federal lawsuit and price target cut amid legal scrutiny over billing and data practices
Hims & Hers Health is under federal investigation and lawsuit for alleged deceptive billing, difficult subscription cancellations, and unauthorized sharing of health data with advertisers. Barclays lowered its price target from $39 to $35, reflecting...


